Test Price
2,800 AED✅ Home Collection Available
TNFRSF11A Gene: Familial Expansile Osteolysis – Next‑Generation Sequencing (NGS)
Executive Summary & Core Metrics
✅ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO-Accredited NGS Processing.
🚑 Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Daily 8 AM – 11 PM).
📞 Clinical Guidance: Telephonic Post-Test Clinical Guidance in Result Interpretation.
📋 Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
Precision Next‑Gen Sequencing for Rare Bone & Skin Disorders
This genetic test screens the TNFRSF11A gene for mutations causing familial expansile osteolysis (FEO) — a disorder presenting with progressive bone destruction, deafness, and skin lesions. Using high‑depth NGS, it delivers definitive molecular diagnosis for patients, at‑risk relatives, and research applications.
| Feature | Our Test | Closest Alternative |
|---|---|---|
| Precision | 99.9% sensitivity, complete coding region | Sanger sequencing of hotspots only |
| Methodology | NGS (Illumina platform) | Sanger sequencing |
| Speed | 3–4 weeks with clinical report | 6–8 weeks, limited interpretation |
Physician Insight & Safety Protocols
“As a DHA‑licensed Consultant Medical Genetics (DHA: 9294403), I emphasize that genetic testing for TNFRSF11A mutations must be correlated clinically with bony pain, deformity, or characteristic skin lesions. This test forms one piece of a comprehensive evaluation by a Medical Geneticist, Rheumatologist, or Dermatologist.” — Lina Osama Zaki Quteineh
Advisory Precautions
⚠️ Important Medication Advisory
Do not alter or discontinue any prescribed therapy without prior consultation with your treating physician. Genetic test results should be interpreted in conjunction with clinical findings and medication history.
Exclusion Criteria & Emergency Indicators
🛡️ Safety & Exclusion Criteria
- This test is not a standalone screening tool; a pre‑test genetic counselling session is mandatory.
- Exclusion: patients unable to provide informed consent, or samples that do not meet collection standards.
- ER Red Flags: Sudden severe bone pain, pathological fracture, acute swelling/immobility warrant immediate emergency care.
Patient FAQ & Clinical Guidance
1. What is the TNFRSF11A gene test for familial expansile osteolysis?
This NGS‑based genetic test identifies mutations in the TNFRSF11A gene responsible for familial expansile osteolysis, enabling early diagnosis and family screening. The assay covers all coding exons and splice sites, providing a definitive molecular diagnosis for patients with suspected FEO, associated bone disorders, or overlapping dermatologic and immunologic symptoms. Once a pathogenic variant is detected, at‑risk relatives can undergo targeted testing.
2. How is the test performed and what sample is required?
A simple blood draw is sufficient for DNA extraction and NGS analysis. Our certified phlebotomists collect samples in your home (8 AM – 11 PM) using ISO‑compliant cold‑chain transport. Alternatively, you may provide previously extracted DNA under strict chain‑of‑custody.
3. What is the turnaround time and price?
Results are delivered within 3 to 4 weeks at a cost of 2,800 AED, inclusive of pre‑ and post‑genetic counselling. The final report includes variant interpretation according to ACMG guidelines and clinical recommendations. Direct insurance billing verification is available via WhatsApp.
4. Is pre‑test genetic counselling mandatory?
Yes, pre‑test genetic counselling is mandatory for this test. A DHA‑licensed genetics professional will discuss the implications, possible outcomes, and limitations of the analysis before sample collection to ensure informed consent.
5. Can this test detect all known TNFRSF11A mutations?
This NGS assay covers all coding exons and flanking splice sites of the TNFRSF11A gene. It detects single‑nucleotide variants and small insertions/deletions with high sensitivity. Large rearrangements may require complementary testing if clinically indicated.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This service adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent are governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability. All genetic data is encrypted, access‑restricted, and processed exclusively within UAE‑based secure servers.
Clinical & Logistical Metadata
| Test Name | TNFRSF11A Gene Sequencing (Familial Expansile Osteolysis) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 – 4 Weeks |
| Sample Type / Matrix | Whole Blood (Peripheral) – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Daily 8 AM – 11 PM) |
| Methodology Used | Next‑Generation Sequencing (NGS) – Illumina Platform, High‑Depth Coverage |
| ICD-10-CM Code | M89.58, Q78.8, Z15.89 |
| LOINC Code | 78337-6 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians